Analysis of clinical outcomes of two antiEGFR antibodies, cetuximab and panitumumab, in the 1st line chemotherapy of RAS wild metastatic colorectal cancer, by neutrophil-to-lymphocyte ratio (NLR) kinetics

MLA

Shinya Hamasu, et al. “Analysis of Clinical Outcomes of Two AntiEGFR Antibodies, Cetuximab and Panitumumab, in the 1st Line Chemotherapy of RAS Wild Metastatic Colorectal Cancer, by Neutrophil-to-Lymphocyte Ratio (NLR) Kinetics.” Annals of Oncology, vol. 29, June 2018, p. v63. EBSCOhost, https://doi.org/10.1093/annonc/mdy151.223.

APA

Shinya Hamasu, Dai Manaka, Y. Nishikawa, H. An, Sayuri Konishi, K. Kawaguchi, T. Ota, Ryuta Nishitai, & Ryo Kudo. (2018). Analysis of clinical outcomes of two antiEGFR antibodies, cetuximab and panitumumab, in the 1st line chemotherapy of RAS wild metastatic colorectal cancer, by neutrophil-to-lymphocyte ratio (NLR) kinetics. Annals of Oncology, 29, v63. https://doi.org/10.1093/annonc/mdy151.223

Chicago

Shinya Hamasu, Dai Manaka, Y. Nishikawa, H. An, Sayuri Konishi, K. Kawaguchi, T. Ota, Ryuta Nishitai, and Ryo Kudo. 2018. “Analysis of Clinical Outcomes of Two AntiEGFR Antibodies, Cetuximab and Panitumumab, in the 1st Line Chemotherapy of RAS Wild Metastatic Colorectal Cancer, by Neutrophil-to-Lymphocyte Ratio (NLR) Kinetics.” Annals of Oncology 29 (June): v63. doi:10.1093/annonc/mdy151.223.